Cancer Research UK has awarded a 20-million-pound grant (about $26 million U.S.) to a team of international investigators, including Vanderbilt’s James Goldenring, MD, PhD, to study inflammation-related cancers.
News: Gastrointestinal Cancer
Mary Philip, MD, PhD, has been named a 2019 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.
In an article recently published in Cell Reports, James G. Patton, PhD, and colleagues studied how colon cancer cells can secrete long RNAs in carefully regulated ways.
A trans-institutional team of researchers at Vanderbilt University Medical Center and Vanderbilt University has received an $11 million Cancer Moonshot grant to build a single-cell resolution atlas to map out the routes that benign colonic polyps take to progress to colorectal cancer.
The signs of this rare bile-duct cancer typically go unnoticed at first. Here’s what to know.
A recent study has linked inflammation-driven carcinogenesis in the colon to loss of an important signaling protein called SMAD4.
Sirtex Medical Ltd. has renewed a grant award to Dan Brown, MD, professor of Radiology and Radiological Sciences and chief of Interventional Oncology, and his Vanderbilt Health colleagues, for a research program designed to treat patients with liver tumors that cannot be addressed with surgery.
Richard Peek, MD, director of the Vanderbilt Digestive Disease Research Center (VDDRC) and chief of the Division of Gastroenterology, Hepatology and Nutrition, has been appointed to serve on the advisory council of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Calcium plays key roles in cellular signaling, proliferation and death. Previous studies exploring the relationship between dietary calcium intake and colorectal cancer have had contradictory results, perhaps due to no consideration of variation in calcium reabsorption by the kidney.
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.